Metronidazole Global Market Report 2025

The metronidazole market size has grown strongly in recent years. It will grow from $0.58 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historic period can be attributed to favorable healthcare reimbursement policies, increased funding for infectious disease research, a rising incidence of oral and dental infections, a growing prevalence of inflammatory bowel diseases, and an expanding elderly population.

The metronidazole market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the rising prevalence of bacterial and protozoal infections, increasing cases of gastrointestinal disorders, growing demand for affordable generic antibiotics, expanding healthcare infrastructure, and government initiatives to combat infectious diseases. Key trends expected in this period include advancements in pharmaceutical manufacturing, strategic collaborations among pharmaceutical companies, the expansion of pharmaceutical contract manufacturing organizations, the adoption of nanotechnology-based drug delivery systems, and innovations in pH-responsive metronidazole formulations.

The rising incidence of bacterial infections is expected to drive the growth of the metronidazole market. Bacterial infections occur due to the proliferation of harmful bacteria in the body, and their increasing prevalence is attributed to factors such as antibiotic resistance, environmental changes, and a growing immunocompromised population. Metronidazole works by targeting bacterial DNA, disrupting its replication and spread, making it highly effective against anaerobic bacteria and certain protozoal infections. For instance, according to the UK Health Security Agency (UKHSA), a UK-based government agency, an estimated 58,224 individuals in England were affected by antibiotic-resistant infections in 2022, marking a 4% increase from 55,792 cases in 2021. Additionally, deaths from severe antibiotic-resistant infections rose from 2,110 in 2021 to 2,202 in 2022. As a result, the growing prevalence of bacterial infections is expected to fuel the expansion of the metronidazole market.

Key players in the metronidazole market are focusing on advancing drug formulations to improve patient compliance. Innovations such as ready-to-use oral liquids are being developed to enhance ease of administration, particularly for patients who have difficulty swallowing tablets or require a more convenient treatment option. Ready-to-use oral liquids eliminate the need for additional preparation or mixing, simplifying medication adherence. For example, in November 2023, Kesin Pharma Corporation, a US-based specialty pharmaceutical company, received FDA approval for LIKMEZ (metronidazole) oral suspension, 500 mg/5 mL. This novel formulation is designed to improve patient adherence and is approved for treating trichomoniasis and anaerobic bacterial infections in adults, as well as amebiasis in adults and children. LIKMEZ is available as a strawberry peppermint-flavored suspension in a 200 mL bottle with a 24-month shelf life and does not require refrigeration.

In April 2023, Marksans Pharma, an India-based pharmaceutical company, acquired a manufacturing facility from Teva Pharmaceutical Industries for an undisclosed amount. This acquisition is expected to double Marksans’ existing production capacity from 8 billion units per year. Teva Pharmaceutical Industries is an India-based pharmaceutical company that manufactures metronidazole tablets.

Major players in the metronidazole market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Fresenius Kabi AG, Baxter International Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences, YiChang HEC ChangJiang Pharmaceutical Co. Ltd., Aarti Drugs Ltd., Unichem Laboratories, Cosette Pharmaceuticals Inc., Saptalis Pharmaceuticals LLC, Huanggang Saikang Pharmaceutical Co. Ltd., Kesin Pharma, Hubei Hongyuan Pharmaceutical Technology Co. Ltd., Huanggang Yinhe Aarti Pharmaceutical Co. Ltd., and Higgs Healthcare.

Asia-Pacific was the largest region in the metronidazole market in 2024. The regions covered in metronidazole report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metronidazole market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metronidazole is an antibiotic and antiprotozoal medication used to treat bacterial and parasitic infections. It functions by penetrating microbial cells, where bacterial and protozoal enzymes reduce it, producing reactive nitrogen species. These reactive compounds damage DNA, leading to strand breakage and the inhibition of nucleic acid synthesis, ultimately disrupting replication and transcription, resulting in cell death.

The primary formulations of metronidazole include tablets, capsules, intravenous (IV) solutions, topical creams or ointments, and others. Metronidazole tablets are oral medications used to treat bacterial and parasitic infections, providing sustained effects for convenient and effective outpatient treatment. They are utilized for various applications, including bacterial infections, parasitic infections, gynecological infections, surgical prophylaxis, and more. The drug is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used by various end-users, including hospitals, clinics, homecare, and others.

The metronidazole market research report is one of a series of new reports that provides metronidazole market statistics, including the metronidazole industry global market size, regional shares, competitors with the metronidazole market share, detailed metronidazole market segments, market trends, and opportunities, and any further data you may need to thrive in the metronidazole industry. This metronidazole market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metronidazole market consists of sales of oral suspension, suppositories, and gel. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.